Search

Overview Throat cancer refers cancer that develops in your throat (pharynx) or voice box (larynx). Your throat is a muscular tube that begins behind your nose and ends in your [...]

2024 OCT 1 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Researchers detail new data in oral cancer. According to news reporting out of the University [...]

Drug & Device Pipeline News Company Drug/Device Medical Condition COVID-19 Trials and Actions Nektar bempegaldesleukin adults diagnosed with Therapeutics (NKTR-214) mild COVID-19 infection Nitric Oxide NOviricid, 30 mg African Americans [...]

SAN FRANCISCO: Nektar Therapeutics has issued the following press release: Nektar Therapeutics (NASDAQ:NKTR) today announced that the first patient has been dosed in the Phase 1/2 trial of NKTR-255, Nektar's [...]

(GlobeNewswire) - Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company) today announced that it will present additional data on its lead partnered asset, monalizumab, [...]

(GlobeNewswire) - Antios Therapeutics, Inc. (Antios) today announced the appointment of Gregory T. Mayes as Chief Executive Officer and Director. Mr. Mayes succeeds Abel De La Rosa, Ph.D., who co-founded [...]

Contract Awarded for Cetuximab Title : Cetuximab Quantity: 20.00 AMPOLLA Unit Price without taxes: U$S 1.439,97 Contractor name : TERGEN S.A. (RUT 215914680014) Contractor address : Uruguay Implementing agency : [...]

London: King's College London has issued the following news release: Head and neck cancers (HNC) are a prevalent malignancy with significant unmet medical needs. Although the prevalence of smoking associated [...]

Prior information notice without call for competition: Various medicinal products Description of the procurement: Cetuximab drug. II.1.6)Information about lots This contract is divided into lots: no Major organization : SERVICIO [...]

The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending BRAFTOVI(encorafenib) plus cetuximab, within its marketing authorisation, as an option for treating BRAFV600E [...]

PARIS & CAMBRIDGE, Mass. -- Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN : FR0011341205 - the ''Company''), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, [...]

Contract awarded for 8201n001-inj. cetuximab 5 mg./ml., 20 ml. in vial packing. firm~~~~s offer: brand as accepted: erbitux 100 mg. mfgd. by m/s. merck kgaa, germany. imported & mktd. by [...]

* Two new studies have received 'Safe to Proceed' notifications from the United States Food and Drug Administrations and are pending activation: * A phase II study of NBTXR3 activated [...]

* Positive new data from two (2) pre-clinical presentations delivered at The Society for the Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting: * Modulation of TCR Repertoire by Radiotherapy-activated [...]

(GlobeNewswire) - Receptor Life Sciences (Receptor) today announced the appointment of Gregory T. Mayes, J.D. to its Board of Directors. Mr. Mayes is an expert in biopharmaceutical industry business strategy [...]

Contract awarded for 4180472/2020-aq. Central c976 - cetuximab 100 mg sol inj 20 ml frs amp Date of conclusion of the contract: 14-10-2020 Contract price: 20. 646,60 Deadline: 2 days [...]

SEATTLE, Nov 11, 2020 (GLOBE NEWSWIRE via COMTEX) -- Receptor Life Sciences (Receptor) today announced the appointment of Gregory T. Mayes, J.D. to its Board of Directors. Mr. Mayes is [...]

TEL AVIV, Israel, Nov 11, 2020 (GLOBE NEWSWIRE via COMTEX) -- Kitov Pharma Ltd. ('Kitov') (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug [...]

Data presented at The Society for the Immunotherapy of Cancer 35th Anniversary Annual Meeting * Eight of nine patients treated on the study to date showed tumor regression, including six [...]

(GlobeNewswire) - Kitov Pharma Ltd. (Kitov) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the company and Bristol Myers [...]

TEL AVIV, Israel, Nov 09, 2020 (GLOBE NEWSWIRE via COMTEX) -- Kitov Pharma Ltd. ('Kitov') (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug [...]

(GlobeNewswire) - Kitov Pharma Ltd.(Kitov) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced receipt of a Notice of Allowance from [...]

SAN DIEGO: Mirati Therapeutics, Inc. has issued the following news release: Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced preliminary results from the Company's mutant KRAS [...]

TEL AVIV, Israel, Oct 27, 2020 (GLOBE NEWSWIRE via COMTEX) -- Patent covers NT219's combinations with multiple 2 and 3 generation EGFR inhibitors, including osimertinib (TAGRISSO(R)) Kitov Pharma Ltd. ('Kitov') [...]

(GlobeNewswire) - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, reported new preclinical data demonstrating the Companys [...]

SAN DIEGO, Oct 26, 2020 (GLOBE NEWSWIRE via COMTEX) -- - Preclinical data support potential to expand therapeutic utility of tipifarnib to HRAS/PI3K dependent tumors representing up to 50% of [...]

* Nanobiotix global development plan for first-in-class radioenhancer NBTXR3 across several solid tumor indications proceeds as planned with focus on priority pathways in head and neck cancer and immunotherapy * [...]

(GlobeNewswire) - Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) has dosed the first patient in its Phase [...]

MARSEILLE, France, Oct 23, 2020 (GLOBE NEWSWIRE via COMTEX) -- Milestone payment further bolsters Innate's cash position INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients [...]

* First patient injected in phase I trial evaluating NBTXR3 activated by radiation therapy for patients with pancreatic cancer at The University of Texas MD Anderson Cancer Center in clinical [...]

Germany: Merck KGaA has issued the following press release: New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO(r)* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in [...]

Merck, a leading science and technology company, today announced more than 30 abstracts will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19-21. [...]

Amsterdam: INNATE PHARMA has issued the following news release: Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) ('Innate' or the 'Company') today reported its consolidated financial results [...]

(GlobeNewswire) - Kitov Pharma Ltd. (Kitov) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the first patient has been [...]

(GlobeNewswire) - Innate resumed enrollment of lacutamab TELLOMAK Phase 2 clinical trial for patients with Szary syndrome and mycosis fungoides Monalizumab Phase 3 study expected to initiate in the second [...]

AVEO Oncology (Nasdaq: AVEO) today announced that it has regained full global rights to ficlatuzumab, AVEOs potent hepatocyte growth factor (HGF) inhibitory antibody which binds to the HGF ligand with [...]

The National Institute for Health and Care Excellence has published the outcome of an appraisal of Pierre Fabre's Braftovi (encorafinib), turning down NHS funding for the drug as a treatment [...]

Byline: Nick Paul Taylor Aveo Oncology has regained (https://www.businesswire.com/news/home/20200908005259/en/AVEO-Oncology-Regains-Full-Global-Rights-Ficlatuzumab) the full global rights to ficlatuzumab. Biodesix was co-developing the hepatocyte growth factor inhibitory antibody with Aveo but has chosen to [...]

Announces Decision to Fund Clinical Manufacture of Ficlatuzumab for Potential Phase 3 Study and Update to Biodesix Partnership No Change to AVEO Cash Runway Guidance BOSTON -- AVEO Oncology (Nasdaq: [...]

TEL AVIV, Israel, Sep 08, 2020 (GLOBE NEWSWIRE via COMTEX) -- Kitov Pharma Ltd. ('Kitov') (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug [...]

The Institute of Cancer Research, London, has welcomed the approval by the Scottish Medicines Consortium (SMC) of the immunotherapy, pembrolizumab, as a first-line NHS treatment for some patients with head [...]

A drug combination for people with a rare type of bowel cancer has received an initial rejection from the National Institute for Health and Care Excellence (NICE). The targeted treatment [...]

(GlobeNewswire) - Kitov Pharma Ltd.(Kitov) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced receipt of notification from the Chinese Patent [...]

TEL AVIV, Israel, Sep 04, 2020 (GLOBE NEWSWIRE via COMTEX) -- Kitov's patent coverage for CM24 and NT219 now extends to the U.S., EU, China, and multiple ROW countries Kitov [...]

(GlobeNewswire) - Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced its financial results for the six [...]

-- Supplemental NDAs for Toripalimab filed -- Expanding into infectious disease and collaborating with IMCAS and Lilly for COVID-19 neutralizing antibodies -- Dual Listing on the STAR Market HONG KONG, [...]

SHANGHAI, China, Aug 30, 2020 (GLOBE NEWSWIRE via COMTEX) -- -- Supplemental NDAs for Toripalimab filed -- Expanding into infectious disease and collaborating with IMCAS and Lilly for COVID-19 neutralizing [...]

(GLOBE NEWSWIRE via COMTEX) -- -- Supplemental NDAs for Toripalimab filed -- Expanding into infectious disease and collaborating with IMCAS and Lilly for COVID-19 neutralizing antibodies -- Dual Listing on [...]

Hong Kong: Mabpharm Limited has issued the following announcement: The Board of Mabpharm Limited is pleased to announce the unaudited consolidated financial results of the Company and its subsidiaries for [...]